首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
【24h】

The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster

机译:基于TCM网络药理学和验证实验的武威青玉肝枢嘧虫潜在机制及高脂血症仓鼠验证实验

获取原文
           

摘要

Wuwei Qingzuo San (WWQZS), as a renowned traditional Mongolian patent medicine approved by Chinese State Food and Drug Administration, is used to treat hyperlipidemia, indigestion, and other ailments related to disorder of production of essence and phlegm, a typical abnormal metabolism of blood in traditional Mongolian medicine. A combination of network pharmacology and validation experiments in hyperlipidemia hamster is used to understand the potential mechanism of WWQZS for hypolipidemic effects, further for an integrated concept of traditional theory, bioactive constituents, and molecular mechanism for TMM. Through network pharmacology, we obtained 212 components, 219 predicted targets, and 349 known hyperlipidemia-related targets form public database and used Metascape to carry out enrichment analysis of 43 potential and 45 candidate targets to imply numerous BP concerned with metabolism of lipid, regulation of kinases and MF related to lipid binding, phosphatase binding, and receptor ligand activity that are involved in anti-hyperlipidemia. In addition, KEGG pathways that explicated hypolipidemic effect were involved in pathways including metabolism associated with kinase function according to MAPK signaling pathway, AMPK signaling pathway, and PI3K-Akt signaling pathway. Meanwhile, in HFD-induced hamster model, WWQZS could significantly reduce TC and ALT and help decrease TG, LDL-C as well; liver pathological section implied that WWQZS could relieve liver damage and lipid accumulation. Western blot indicated that WWQZS may upregulate CYP7A1 and activate AMPK to suppress the expression of HMGCR in livers. In conclusion, our results suggest that WWQSZS plays important dual hypolipidemic and liver-protective role in livers in HFD-induced hamster model. Through this research, a new reference is also provided to other researches in the study of ethnopharmacology.
机译:武威青佐·圣(WWQZS)作为中国国家食品和药物管理局批准的着名传统蒙古专利医学,用于治疗高脂血症,消化不良等疾病,与本质和痰的生产无序相关,典型的异常代谢血液在传统的蒙古医学中。高脂血症仓鼠网络药理学和验证实验的组合用于了解WWQZ对低血脂作用的潜在机制,进一步用于传统理论,生物活性成分和TMM分子机制的综合概念。通过网络药理学,我们获得了212个组分,219个预测的目标和349个已知的高脂血症相关的目标,形成了公共数据库,并使用FearAscape进行了43个潜力和45名候选目标的富集分析,暗示了许多与脂质代谢有关的BP,调节与脂质结合,磷酸酶结合和参与抗高脂血症相关的受体配体活性相关的激酶和MF。此外,显着的癫痫发作效应的Kegg途径涉及途径,包括根据MAPK信号通路,AMPK信号通路和PI3K-AKT信号通路与激酶功能相关的代谢。同时,在HFD诱导的仓鼠模型中,WWQS可以显着降低TC和ALT,并帮助减少TG,LDL-C;肝脏病理部分暗示,WWQS可以缓解肝损伤和脂质积累。 Western印迹表明WWQS可能上调CYP7A1并激活AMPK以抑制肝脏中HMGCR的表达。总之,我们的研究结果表明,WWQSZ在HFD诱导的仓鼠模型中发挥着重要的双重低血脂和肝脏保护作用。通过这项研究,还向其他研究中提供了新的参考研究了民族科医药学的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号